Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

November 30, 2026

Primary Completion Date

June 30, 2028

Study Completion Date

November 30, 2028

Conditions

Metastatic Colorectal Cancer

Interventions

BIOLOGICAL

AlloStim

experimental immunotherapy to prime for checkpoint inhibitor

DRUG

Bavencio

anti-PDL1 checkpoint inhibitor

Trial Locations (3)

Hirschfield Oncology Center, Brooklyn

New York Cancer and Blood Specialists, Shirley

Mt. Sinai Comprehensive Cancer Center, Miami Beach